Condition Directory

Colorectal Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Colorectal Cancer. Browse Colorectal Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 5, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3452

Shown on this page

Current sort

How Colorectal Cancer studies are organized in the registry

Records may be registered under “colorectal,” “colon,” or “rectal” cancer — the three terms overlap but are not interchangeable in search, so check more than one if your interest spans them. Molecular labels (MSI-high, KRAS, BRAF) and the abbreviation mCRC for metastatic disease appear frequently in titles.

Terms that often appear in related listings

colon cancer rectal cancer MSI-high mCRC

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 661–672 of 3,452 matching trials for Colorectal Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Colorectal Cancer Metastatic
Interventions: Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373; Combination Product
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Lake Success, New York • New Hyde Park, New York

Conditions: Colorectal Cancer, Metastatic Colorectal Cancer
Interventions: Tovecimig, Irinotecan, Leucovorin, 5-Fluorouracil (5-FU); Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Female Breast Cancer, Prostate Cancer, Colorectal Carcinoma
Interventions: Culturally adapted Online Genetic Counseling and Testing Information; Behavioral
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 20 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Colorectal Cancer Prevention, Colorectal Adenoma
Interventions: Increased Plant-Based Diet and Decreased Animal-Based Diet; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Interventions: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion; Drug
Lead sponsor: RasCal Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Nashville, Tennessee

Conditions: Adenocarcinoma of the Colon, Stage III Colon Cancer
Interventions: irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, cetuximab, Locally Directed Therapy; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 3,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 858
States / cities: Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 538 more

Conditions: Colorectal Cancer
Interventions: Aspirin, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer, Ampullary Cancer
Interventions: FOX dose-escalation algorithm; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Colorectal Carcinoma
Interventions: Best Practice, Educational Intervention, Electronic Health Record Review, Interview, Supportive Care, Survey Administration; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
Interventions: XMT-2056; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Stanford, California • Celebration, Florida + 8 more

Conditions: Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions: IDE034; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more

About this Colorectal Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Colorectal Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Colorectal Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Colorectal Cancer clinical trials

How Colorectal Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer

A Multilevel Intervention to Increase Colorectal Cancer Screening Tests in Patients With Abnormal Fecal Immunochemical Test Results, PROACT Trial

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

About this Colorectal Cancer clinical trials directory page